Leukemia - Table of Contents alert Volume 32 Issue 11

Advertisement See how droplets are guiding precision medicine  Liquid biopsy promises a new level of precision in disease profiling and drug resistance monitoring. Is your lab using this tool to its full potential? See how a promising new technology lets you give clinicians insights that can guide personalized cancer treatments. TABLE OF CONTENTS Volume 32, Issue 11 In this issue Review Article Article Brief Communication Also new AOP Advertisement   Now Enrolling - Clinical studies for oral pracinostat in Acute Myeloid Leukemia (AML) Patients Unfit for Induction Chemotherapy and in Myelodysplastic Syndromes (MDS) trials Pracinostat is an investigational agent not approved for commercial use by the FDA or any other regulatory agency worldwide PRAN-US-0024 Review Article CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells Marion Alcantara, Melania Tesio, Carl H. June & Roch Houot Leukemia 2018 32 :2307 - 2315; October 12, 2018; 10.1038/s41375-018-0285-8 Abstract | Full Text Article Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study Weili Sun, Jemily Malvar, Richard Sposto, Anupam Verma, Jennifer J. Wilkes et al. Leukemia 2018 32 :2316 - 2325; March 15, 2018; 10.1038/s41375-018-0094-0 Abstract | Full Text New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment Laurence C. Cheung, Jennifer Tickner, Anastasia M. Hughes, Patrycja Skut, Meegan Howlett et al. Leukemia 2018 32 :2326 - 2338; May 08, 2018; 10.1038/s41375-018-0144-7 Abstract | Full Text UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response LN Huiting, Y Samaha, GL Zhang, JE Roderick, B Li et al. Leukemia 2018 32 :2339 - 2351; April 25, 2018; 10.1038/s41375-018-0141-x Abstract | Full Text Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Pamela S. Becker et al. Leukemia 2018 32 :2352 - 2362; April 17, 2018; 10.1038/s41375-018-0135-8 Abstract | Full Text FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome Tianxiang Hu, Qing Wu, Yating Chong, Haiyan Qin, Candace J. Poole et al. Leukemia 2018 32 :2363 - 2373; April 02, 2018; 10.1038/s41375-018-0124-y Abstract | Full Text Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes Mona M. Hosseini, Stephen E. Kurtz, Sherif Abdelhamed, Shawn Mahmood, Monika A. Davare et al. Leukemia 2018 32 :2374 - 2387; March 29, 2018; 10.1038/s41375-018-0112-2 Abstract | Full Text Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies Philip A. Thompson, Christine B. Peterson, Paolo Strati, Jeff Jorgensen, Michael J. Keating et al. Leukemia 2018 32 :2388 - 2398; April 17, 2018; 10.1038/s41375-018-0132-y Abstract | Full Text Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion William L. Heaton, Anna V. Senina, Anthony D. Pomicter, Mohamed E. Salama, Phillip M. Clair et al. Leukemia 2018 32 :2399 - 2411; April 18, 2018; 10.1038/s41375-018-0131-z Abstract | Full Text High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations V. Pillonel, D. Juskevicius, C. K. Y. Ng, A. Bodmer, A. Zettl et al. Leukemia 2018 32 :2412 - 2426; February 28, 2018; 10.1038/s41375-018-0082-4 Abstract | Full Text Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role Paula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, Nerea Martín-Calvo, Miguel-Teodoro Hernández et al. Leukemia 2018 32 :2427 - 2434; February 23, 2018; 10.1038/s41375-018-0072-6 Abstract | Full Text Kinase domain activation through gene rearrangement in multiple myeloma Gareth J Morgan, Jie He, Ruslana Tytarenko, Purvi Patel, Owen W Stephens et al. Leukemia 2018 32 :2435 - 2444; March 23, 2018; 10.1038/s41375-018-0108-y Abstract | Full Text Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner-Herold, Miriam J. Müller, Dietrich A. Volmer et al. Leukemia 2018 32 :2445 - 2458; March 28, 2018; 10.1038/s41375-018-0114-0 Abstract | Full Text Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms Phuc H. Hoang, Sara E. Dobbins, Alex J. Cornish, Daniel Chubb, Philip J. Law et al. Leukemia 2018 32 :2459 - 2470; April 09, 2018; 10.1038/s41375-018-0103-3 Abstract | Full Text Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS Nasrin Rastgoo, Maryam Pourabdollah, Jahangir Abdi, Donna Reece & Hong Chang Leukemia 2018 32 :2471 - 2482; April 24, 2018; 10.1038/s41375-018-0140-y Abstract | Full Text Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease Jaebok Choi, Matthew L. Cooper, Karl Staser, Kidist Ashami, Kiran R. Vij et al. Leukemia 2018 32 :2483 - 2494; April 02, 2018; 10.1038/s41375-018-0123-z Abstract | Full Text Brief Communication Ninety-minute daratumumab infusion is safe in multiple myeloma Hallie Barr, Jessica Dempsey, Allyson Waller, Ying Huang, Nita Williams et al. Leukemia 2018 32 :2495 - 2518; March 31, 2018; 10.1038/s41375-018-0120-2 Abstract | Full Text Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene Maja Studencka-Turski, Gunter Maubach, Michael Hartmut Feige & Michael Naumann Leukemia 2018 32 :2498 - 2501; April 17, 2018; 10.1038/s41375-018-0128-7 Abstract | Full Text GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML Ahad F. Al Seraihi, Ana Rio-Machin, Kiran Tawana, Csaba Bödör, Jun Wang et al. Leukemia 2018 32 :2502 - 2507; April 19, 2018; 10.1038/s41375-018-0134-9 Abstract | Full Text Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria Michael J. Clemente, Bartlomiej Przychodzen, Cassandra M. Hirsch, Yasunobu Nagata, Taha Bat et al. Leukemia 2018 32 :2507 - 2511; April 25, 2018; 10.1038/s41375-018-0138-5 Abstract | Full Text Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases Mrinal M. Patnaik, Ana A. Pierola, Rangit Vallapureddy, Fevzi F. Yalniz, Tapan M. Kadia et al. Leukemia 2018 32 :2512 - 2518; April 25, 2018; 10.1038/s41375-018-0143-8 Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. This email has been sent to edgeblog.alerts.2011.001@gmail.com. If you no longer wish to receive the email alerts from Leukemia click here to unsubscribe . If you wish to discontinue all email services from Nature Research please click here to unsubscribe . For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.